Danaher reported strong Q1 2026 results with an earnings beat and raised full-year guidance, driven by 7% core revenue growth in Biotechnology. It is advancing the $9.9 billion Masimo acquisition and launching AI-powered Genedata Vico platform. Pall subsidiary received government funding for carbon-capture filtration pilots. Despite these positives, shares remain down 25% year-to-date.